Brief: United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For Miroliverelap® For Treatment Of Acute Liver Failure
08/04/2026 13:12
United Therapeutics Corp UTHR.O: UNITED THERAPEUTICS RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR MIROLIVERELAP® FOR TREATMENT OF ACUTE LIVER FAILURE Source text: ID:nBw5r1D3Ca Further company coverage: UTHR.O
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug